Showing results 4 to 7 of 7
< previous
| Preview | Issue Date | Title / Name | Author(s) | Type |
| May-2022 | RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer | Spigel, David R.; Paz-Ares, Luis; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Journal Article | |
| 2020 | RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) | Ponce, Santiago; Brendel, K.; Spigel, David R.; Chen, Yuanbin; Jove Casulleras, M., et al | Conference Paper | |
| 2020 | RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2020 | RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy | Spigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Conference Paper | |
